In vitro evaluation of a combination treatment involving anticancer agents and an aurora kinase B inhibitor

Sakai,Senna; Izumi,Hiroto; Yoshiura,Yukiko; Nakayama,Yoshifumi; Yamaguchi,Takahiro; Harada,Yoshikazu; Koi,Chiho; Kurata,Hiroyuki; Morimoto,Yasuo

doi:10.3892/ol.2016.5156

In vitro evaluation of a combination treatment involving anticancer agents and an aurora kinase B inhibitor

Authors:
- Senna Sakai
- Hiroto Izumi
- Yukiko Yoshiura
- Yoshifumi Nakayama
- Takahiro Yamaguchi
- Yoshikazu Harada
- Chiho Koi
- Hiroyuki Kurata
- Yasuo Morimoto
View Affiliations

Affiliations: Department of Occupational Pneumology, Institute of Industrial Ecological Science, University of Occupational and Environmental Health School of Medicine, Kitakyushu 807‑8555, Japan, Department of Gastroenterological and General Surgery, Wakamatsu Hospital, University of Occupational and Environmental Health School of Medicine, Kitakyushu 808‑0024, Japan, Department of Hematology, University of Occupational and Environmental Health, Kitakyushu 807‑8555, Japan, Department of Dentistry and Oral Surgery, University Hospital, University of Occupational and Environmental Health, Kitakyushu 807‑8555, Japan, Department of Obstetrics and Gynecology, University of Occupational and Environmental Health School of Medicine, Kitakyushu 807‑8555, Japan, Department of Bioscience and Bioinformatics, Biomedical Informatics R&D Center, Kyushu Institute of Technology, Iizuka, Fukuoka 820‑8502, Japan
Published online on: September 20, 2016 https://doi.org/10.3892/ol.2016.5156
Pages: 4263-4269

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aurora kinase B (AURKB) inhibitors are regarded as potential molecular‑targeting drugs for cancer therapy. The present study evaluated the cytotoxic effect of a combination of AZD1152‑hQPA, an AURKB inhibitor, and various anticancer agents on the HeLa human cervical cancer cell line, as well as its cisplatin‑resistant equivalent HCP4 cell line. It was demonstrated that AZD1152‑hQPA had an antagonistic effect on the cytotoxicity of cisplatin, etoposide and doxorubicin, but had a synergistic effect on that of all‑trans‑retinoic acid (ATRA), Am80 and TAC‑101, when tested on HeLa cells. Cisplatin, etoposide and doxorubicin were shown to increase the cellular expression of AURKB, while ATRA, Am80 and TAC‑101 downregulated its expression. These results suggested that AURKB expression is regulated by these anticancer agents at the transcriptional level, and that the level of expression of AURKB may influence the cytotoxic effect of AZD1152‑hQPA. Therefore, when using anticancer agents, decreasing the expression of AURKB using a molecular‑targeting drug may be an optimal therapeutic strategy.

View Figures

View References

1	Kollareddy M, Dzubak P, Zheleva D and Hajduch M: Aurora kinases: Structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 152:27–33. 2008. View Article : Google Scholar : PubMed/NCBI
2	Hochegger H, Hégarat N and Pereira-Leal JB: Aurora at the pole and equator: Overlapping functions of Aurora kinases in the mitotic spindle. Open Biol. 3:1201852013. View Article : Google Scholar : PubMed/NCBI
3	Vas AC and Clarke DJ: Aurora B kinases restrict chromosome decondensation to telophase of mitosis. Cell Cycle. 7:293–296. 2008. View Article : Google Scholar : PubMed/NCBI
4	Dutertre S, Descamps S and Prigent C: On the role of aurora-A in centrosome function. Oncogene. 21:6175–6183. 2002. View Article : Google Scholar : PubMed/NCBI
5	Carmena M, Ruchaud S and Earnshaw WC: Making the Auroras glow: Regulation of Aurora A and B kinase function by interacting proteins. Curr Opin Cell Biol. 21:796–805. 2002. View Article : Google Scholar
6	Umene K, Banno K, Kisu I, Yanokura M, Nogami Y, Tsuji K, Masuda K, Ueki A, Kobayashi Y, Yamagami W, et al: Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors. Biomed Rep. 1:335–340. 2013.PubMed/NCBI
7	Mehra R, Serebriiskii IG, Burtness B, Astsaturov I and Golemis EA: Aurora kinases in head and neck cancer. Lancet Oncol. 14:e425–e435. 2013. View Article : Google Scholar : PubMed/NCBI
8	Baldini E, Sorrenti S, D'Armiento E, Prinzi N, Guaitoli E, Favoriti P, Gnessi L, Moretti C, Bianchini M, Alessandrini S, et al: Aurora kinases: New molecular targets in thyroid cancer therapy. Clin Ter. 163:e457–e462. 2012.PubMed/NCBI
9	Kelly KR, Ecsedy J, Mahalingam D, Nawrocki ST, Padmanabhan S, Giles FJ and Carew JS: Targeting aurora kinases in cancer treatment. Curr Drug Targets. 12:2067–2078. 2011. View Article : Google Scholar : PubMed/NCBI
10	Cheung CH, Sarvagalla S, Lee JY, Huang YC and Coumar MS: Aurora kinase inhibitor patents and agents in clinical testing: An update (2011–2013). Expert Opin Ther Pat. 24:1021–1038. 2014. View Article : Google Scholar : PubMed/NCBI
11	Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, De Savi C, Roberts NJ, et al: Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem. 50:2213–2224. 2007. View Article : Google Scholar : PubMed/NCBI
12	Lorusso D, Petrelli F, Coinu A, Raspagliesi F and Barni S: A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 133:117–123. 2014. View Article : Google Scholar : PubMed/NCBI
13	Viswanathan AN: Advances in the use of radiation for gynecologic cancers. Hematol Oncol Clin North Am. 26:157–168. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sun C, Chan F, Briassouli P and Linardopoulos S: Aurora kinase inhibition downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic agents. Biochem Biophys Res Commun. 352:220–225. 2007. View Article : Google Scholar : PubMed/NCBI
15	Akiyama M, Izumi H, Wang KY, Yamaguchi T, Kuma A, Kitamura N, Harada Y, Oya R, Yamaguchi K, Iwai Y and Kohno K: Hypersensitivity to aurora kinase inhibitors in cells resistant against platinum- containing anticancer agents. Anticancer Agents Med Chem. 14:1042–1050. 2014. View Article : Google Scholar : PubMed/NCBI
16	Reynolds CP and Maurer BJ: Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med. 110:73–183. 2005.
17	Yamaguchi T, Kurita T, Nishio K, Tsukada J, Hachisuga T, Morimoto Y, Iwai Y and Izumi H: Expression of BAF57 in ovarian cancer cells and drug sensitivity. Cancer Sci. 106:359–366. 2015. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK and Hu W: Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther. 13:1034–1041. 2012. View Article : Google Scholar : PubMed/NCBI
20	Fiskus W, Hembruff SL, Rao R, Sharma P, Balusu R, Venkannagari S, Smith JE, Peth K, Peiper SC and Bhalla KN: Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. Breast Cancer Res Treat. 135:433–444. 2012. View Article : Google Scholar : PubMed/NCBI
21	Zhang L and Zhang S: ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin. J Obstet Gynaecol Res. 37:591–600. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kimura M, Uchida C, Takano Y, Kitagawa M and Okano Y: Cell cycle-dependent regulation of the human aurora B promoter. Biochem Biophys Res Commun. 316:930–936. 2004. View Article : Google Scholar : PubMed/NCBI
23	Ianari A, Gallo R, Palma M, Alesse E and Gulino A: Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage. J Biol Chem. 279:30830–30835. 2004. View Article : Google Scholar : PubMed/NCBI
24	Real S, Espada L, Espinet C, Santidrián AF and Tauler A: Study of the in vivo phosphorylation of E2F1 on Ser403. Biochim Biophys Acta. 1803:912–918. 2010. View Article : Google Scholar : PubMed/NCBI
25	Hartman J, Müller P, Foster JS, Wimalasena J, Gustafsson JA and Ström A: HES-1 inhibits 17beta-estradiol and heregulin-beta1-mediated upregulation of E2F-1. Oncogene. 23:8826–8833. 2004. View Article : Google Scholar : PubMed/NCBI
26	Sorenson CM, Barry MA and Eastman A: Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst. 82:749–755. 1990. View Article : Google Scholar : PubMed/NCBI
27	Nam C, Doi K and Nakayama H: Etoposide induces G2/M arrest and apoptosis in neural progenitor cells via DNA damage and an ATM/p53-related pathway. Histol Histopathol. 25:485–493. 2010.PubMed/NCBI
28	Ling YH, el-Naggar AK, Priebe W and Perez-Soler R: Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol. 49:832–841. 1996.PubMed/NCBI
29	Wang JG, Barsky LW, Davicioni E, Weinberg KI, Triche TJ, Zhang XK and Wu L: Retinoic acid induces leukemia cell G1 arrest and transition into differentiation by inhibiting cyclin-dependent kinase-activating kinase binding and phosphorylation of PML/RARalpha. FASEB J. 20:2142–2144. 2006. View Article : Google Scholar : PubMed/NCBI
30	Nakazato T, Okudaira T, Ishikawa C, Nakama S, Sawada S, Tomita M, Uchihara JN, Taira N, Masuda M, Tanaka Y, et al: Anti-adult T-cell leukemia effects of a novel synthetic retinoid, Am80 (Tamibarotene). Cancer Sci. 99:2286–2294. 2008. View Article : Google Scholar : PubMed/NCBI
31	Fujimoto K, Hosotani R, Doi R, Wada M, Lee JU, Koshiba T, Miyamoto Y, Tsuji S, Nakajima S and Imamura M: Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells. Int J Cancer. 81:637–644. 1999. View Article : Google Scholar : PubMed/NCBI